Indium-111 Pentreotide
PreclinicalRadiopharmaceutical
Indium-111 Pentreotide is one of 10 small molecule programs targeting Cardiac Sarcoidosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Cardiac Sarcoidosis
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Approved
Trexall
Jazz PharmaceuticalsPhase 3
Olumiant
Eli LillyPhase 2
Arcalyst
KKiniksa Pharmaceuticals (UK), Ltd.
Phase 2
Prednisone or Prednisolone
Johnson & JohnsonPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Inpefa
LLexicon Pharmaceuticals
Preclinical
Tc-99m Tilmanocept
NNavidea Biopharmaceuticals
Phase 2
Gallium-68 DOTATATE
SStanford University
Preclinical
Indium-111 Pentreotide
MMarcelo F. Di Carli, MD, FACC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Indium-111 Pentreotide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Preclinical[1]
- Company
- MMarcelo F. Di Carli, MD, FACC